Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9266408 | 0.89 | GPR119 (0.47) | GPR119ALDH1A1CHEK2HTTPDE4A | |
| SCHEMBL15253534 | 0.88 | GPR119 (0.56) | GPR119 | |
| SCHEMBL8532708 | 0.81 | CHEK2 (0.45) | GPR119ALDH1A1CHEK2PDE4APDE4B | |
| SCHEMBL8530128 | 0.81 | CHEK2 (0.46) | GPR119CHEK2PDE4APDE4BPDE4C | |
| SCHEMBL8535619 | 0.80 | HRH3 (0.35) | GPR119HRH3 | |
| SCHEMBL8534642 | 0.80 | GPR119 (0.45) | GPR119CHEK2 | |
| SCHEMBL9250289 | 0.79 | GPR119 (0.59) | GPR119 | |
| SCHEMBL8536669 | 0.79 | GPR119 (0.48) | GPR119CHEK2HRH3PIK3CD | |
| SCHEMBL15253090 | 0.79 | GPR119 (0.58) | GPR119CHEK2 | |
| SCHEMBL15253238 | 0.79 | CHEK2 (0.44) | GPR119CHEK2PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9000175-B2 | Bicyclic GPR119 modulators | LUPIN LIMITED (IN) | 2015-04-07 | — | — | US | disclosed |
| EP-2643311-A1 | BICYCLIC GPR119 MODULATORS | Lupin Limited (IN) | 2013-10-02 | — | — | EP | disclosed |
| US-20130245000-A1 | BICYCLIC GPR119 MODULATORS | LUPIN LIMITED (IN) | 2013-09-19 | — | — | US | disclosed |
| WO-2012069917-A1 | BICYCLIC GPR119 MODULATORS | LUPIN LIMITED (IN) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245000-A1 | BICYCLIC GPR119 MODULATORS | GPR119, GPR180, GPBAR1 | GPR119 1/4885ALDH1A1 1436/4885CHEK2 3915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.